|
The document outlines DuPont's proposed protocols for well surveying, sampling, and testing related to C8 chemistry, specifically recommending Potesta Associates for the well survey and Battelle Duxbury Operations for environmental sampling.
|
2001 |
AR226-2571
|
8V6Ex0YpbY36rd60V25VbpBDe |
5 |
|
The December 2001 Groundwater Monitoring Report for the Washington Works Facility and local landfills in West Virginia, prepared by DuPont and URS, details the analytical results related to perfluorinated compounds, specifically C-8, in the groundwater.
|
2001 |
AR226-2572
|
wD8Rw9rezQr8MkJoL3em73D0d |
45 |
|
This document is a toxicity study report (DuPont-5206) conducted by E.I. du Pont de Nemours and Company, detailing a 14-day repeated-dose oral toxicity study in mice for a substance related to PFOA/PFOS, completed on June 13, 2001.
|
2001 |
AR226-2802
|
3N8KRdGnddZZXv63zen71L86E |
77 |
|
This document is a biopersistence screening study report conducted by DuPont on perfluorinated compounds, specifically detailing a 20-dose oral gavage study in rats with a recovery period, authored by Susan A. MacKenzie and completed on August 9, 2001.
|
2001 |
AR226-2803
|
YrdEMVgoy5xDX4ga8dQy6oNdK |
65 |
|
The memorandum outlines a collaborative agreement between the Ohio Environmental Protection Agency, West Virginia Department of Environmental Protection, West Virginia Department of Health and Human Resources, and E.I. du Pont de Nemours Company regarding the enforcement of a consent order related to the presence of perfluorooctanoate (C8) in drinking water near DuPont facilities in West Virginia, emphasizing the need for monitoring and developing
|
2001 |
AR226-2580
|
pBbNBqj9XEVeY9O9Xg7aLz3M6 |
3 |
|
3M Company is requesting the redesignation of three studies related to fluorochemicals, including a rat teratology study and two eye irritation studies, to the TSCA Section 8(e) docket, as they supplement previously submitted information on these compounds.
|
2001 |
AR226-3655
|
gayKmG7BVwMEpdbDBx179yw9q |
2 |
|
The document outlines a method for the measurement of ammonium perfluorooctanoate (PFOA) in water and wastewater using solid-phase microextraction and gas chromatography-mass spectrometry (SPME/GCMS), with a limit of quantitation set at 1.0 pg/L.
|
2001 |
AR226-2725
|
v6Bw6nwxvGvnKVobK2k3jKOa8 |
16 |
|
The document outlines a method for extracting perfluorooctanoate (PFOA) from water and wastewater samples using a specific analytical procedure involving MTBE and sulfuric acid for derivatization.
|
2001 |
AR226-2726
|
EqEDBvqBpGmj9G5kKL8wNyZ6g |
12 |
|
The document is a technical report by DuPont de Nemours, Inc. detailing the aquatic toxicity and solubility of a fluorinated polymer intermediate, indicating that the maximum solubility observed was 5 mg/L with no acute toxicity detected in screening tests.
|
2001 |
AR226-3340
|
vBo7KoreqRE0L2r3O9DX20qBq |
143 |
|
The document reports on a bacterial reverse mutation test conducted by BioReliance for E. I. du Pont de Nemours and Company, evaluating the mutagenicity of a test substance related to DuPont Project ID DuPont-5234.
|
2001 |
AR226-3173
|
Z82jLmdr9X7L08VOJkGQbw9Rp |
36 |
|
The document reports on the genetic toxicology evaluation of 8-2 Telomer B Alcohol, a fluorinated chemical used in manufacturing specialty polymers and surfactants, finding no evidence of mutagenicity or toxicity in bacterial and rat tests.
|
2001 |
AR226-3389
|
e1xLj1jEKOoLyJBR9Yrj3z26M |
1 |
|
The document is a final report on an in vitro chromosome aberration test conducted on a substance by E.I. du Pont de Nemours and Company at BioReliance, indicating that the test substance was stable under study conditions.
|
2001 |
AR226-3174
|
2JyBenewEyRXxwZXBO3y8yZoR |
35 |
|
The document reports on a static, acute 48-hour toxicity test of DuPont-6010 (H-24516) on Daphnia magna, revealing that exposure to increasing concentrations of the substance resulted in varying levels of immobility, with 50% immobility observed at the highest concentration of 1000 mg/L.
|
2001 |
AR226-3175
|
nNRy0x2p3z7yqBz42qenpenM1 |
6 |
|
The document reports on a study conducted by E.I. du Pont de Nemours and Company to assess the impact of a test substance (H-24516) on the growth and growth rate of the green alga Selenastrum capricornutum, revealing effects at various concentrations over a 72-hour exposure period.
|
2001 |
AR226-3176
|
OzgjVELe8JJ0ynqkj2Mv2RMkK |
12 |
|
The document reports on a skin irritation test conducted by E. I. du Pont de Nemours and Company on a test substance, evaluating its acute skin irritation potential in rabbits.
|
2001 |
AR226-3177
|
ykBjjz6J1vooq1RYmN7q67v1V |
13 |
|
The document reports on a 96-hour acute toxicity screening test of a perfluorinated compound (H-24616) conducted by DuPont on the fathead minnow (Pimephales promelas), evaluating its effects at various concentrations.
|
2001 |
AR226-3179
|
gDoRnkM0XqRr5ZzB2dgDqYMdG |
5 |
|
The document is an analytical report summarizing the mixing and stability of dosing solutions for a Pilot Developmental Toxicity Study in Rats involving PFOA, confirming that the test substance was mixed properly at the expected concentration of 17%.
|
2001 |
AR226-3178
|
936kvnG33pjkDkwN13R24O2Zq |
13 |
|
The document reports on a developmental toxicity study in rats conducted by E.I. du Pont de Nemours and Company, which assessed the effects of a test substance related to PFOA, confirming its stability and composition during the study while noting some non-compliance with Good Laboratory Practice Standards.
|
2001 |
AR226-3183
|
KJBk9g72Boe555gb6ZOMyxRMw |
149 |
|
This is a DuPont study report (H-24761) detailing a biopersistence screening 10-dose oral gavage study in rats, completed on November 20, 2001, under the direction of Carol Finlay.
|
2001 |
AR226-3190
|
NELmp8Dr3JqYJE76Ky25RR7nV |
83 |
|
The document reports on a static, acute 96-hour toxicity test of the substance DuPont-8838 (a perfluorinated compound) on the fathead minnow, Pimephales promelas, conducted by E.I. du Pont de Nemours and Company, which assessed the effects of various concentrations on the organisms.
|
2001 |
AR226-3191
|
KJk7Xp5GoKR8y6oM1n4y58wdw |
5 |
|
This document is a biopersistence screening study report conducted by E.I. du Pont de Nemours and Company on PFOA, detailing a 10-dose oral gavage study in rats, completed on November 26, 2001.
|
2001 |
AR226-3193
|
b9NEE9r1X9n2180EXYNDj7N0 |
83 |
|
The document is a biopersistence screening study report conducted by DuPont on the effects of a 10-dose oral gavage of a trade secret substance in rats, completed on November 26, 2001.
|
2001 |
AR226-3192
|
O1wL15Ge55QEza40YMV4ngL8X |
84 |
|
The document reports on a subchronic toxicity study conducted by DuPont on rats, evaluating the effects of a perfluorinated compound, with findings indicating various liver lesions at different dosage levels.
|
2001 |
AR226-3185
|
XOQeNwwd83GNVNg1BDO62oJb4 |
314 |
|
The document is a study report by DuPont titled "H-24949: Biopersistence Screening 10-Dose Oral Gavage Study in Rats," which evaluates the biopersistence of a test substance through oral administration in rats, completed on November 26, 2001.
|
2001 |
AR226-3194
|
GmyzDEJL4XeJmB7w208wMv23Y |
83 |
|
The document is a biopersistence screening study report conducted by E.I. du Pont de Nemours and Company on PFOA, detailing a 10-dose oral gavage study in rats, completed on November 26, 2001.
|
2001 |
AR226-3195
|
RjR8a8x31jMNeJXa06rgKb0w8 |
83 |
|
The document reports on a static, acute 48-hour toxicity test of the substance H-25134, conducted by DuPont, which assessed its effects on Daphnia magna, revealing varying concentrations of the substance during the study.
|
2001 |
AR226-3196
|
6QqmbB4R5Y2XY8jZ6Epa2vdd |
5 |
|
The document reports on a subchronic toxicity study conducted by DuPont, indicating minimal inflammation in the liver, chronic progressive nephropathy in the kidneys, and minimal colloid alteration in the thyroid gland in female animals exposed to a test substance, likely related to PFOA or PFOS.
|
2001 |
AR226-3200
|
21700RxoJ1JVEw8rLrRaxnzp |
311 |
|
The document is a supplement report from DuPont detailing a biopersistence screening study of a test substance, likely related to PFOA or PFOS, conducted through a 10-dose oral gavage study in rats, completed in 2001.
|
2001 |
AR226-3206
|
J7bKxQyX4B6D2jd49KjJLekX |
40 |
|
The document reports on the Corrositex In Vitro Test conducted by DuPont on the substance H-25124, concluding that it was not corrosive under the test conditions.
|
2001 |
AR226-3208
|
pr6pJ74MMQmkyaD5mvw5BYdd |
9 |
|
The document is a developmental toxicity study in rats conducted by DuPont (Project ID: DuPont-5991) to assess the effects of a perfluorinated compound, specifically focusing on compliance with good laboratory practices and quality assurance measures.
|
2001 |
AR226-3207
|
pBy12y63rRG2zDo84Qdp4v2LE |
165 |
|
The document reports on a static, acute 96-hour toxicity test conducted by E.I. du Pont de Nemours and Company on the substance H-25134, assessing its effects on the rainbow trout (Oncorhynchus mykiss) at various concentrations.
|
2001 |
AR226-3212
|
b5w6bXb5L8bavOXgVdL1kGe70 |
5 |
|
This is a final report from Covance Laboratories (Study 22900-0-4540ECD) detailing an in vivo rat micronucleus assay conducted between October 18, 2001, and November 19, 2001, for an unspecified sponsor.
|
2001 |
AR226-3226
|
X7Z1j2M3G0nLaeZ6ye1Er8zBg |
31 |
|
The document is a progress report from 3M regarding the phase-out of certain perfluorosulfonyl fluoride (PFOS) derivatives, confirming that as of December 31, 2000, 3M has ceased manufacturing these derivatives in various product categories and is meeting reduced production goals for extended use categories.
|
2001 |
AR226-0997
|
5LxqGbxaMpnvgdnL91kYVDvz5 |
1 |
|
The document is a correspondence from the EPA requesting DuPont Haskell Laboratory to provide the complete data set of blood concentrations related to Ammonium Perfluorooctanoate (AFPO) as summarized in their report.
|
2001 |
AR226-1003
|
rMQm9Jzdx1kDqm6BRmg0qypE |
1 |
|
The document summarizes a March 7, 2001 meeting between the EPA and the Fluoropolymer Manufacturing Group, where concerns were raised about the discontinuation of ammonium perfluorooctanoate (APFO) production by 3M and the need for ongoing toxicology research and risk assessment related to APFO and perfluorooctanoic acid (PFOA).
|
2001 |
AR226-1007
|
mBGYNGpp4GGy3GNdwLdGVZexb |
1 |
|
The document is a facsimile cover letter from Allen C. Weidman of The Society of the Plastics Industry, Inc. (SPI) clarifying the status of Confidential Business Information (CBI) related to submissions on PFOA made to the EPA on April 13, 2001, and March 7, 2001.
|
2001 |
AR226-1008
|
Qk6NY2bLygxrDynzeb2OKK2Qk |
1 |
|
The document is a letter from Allen Weidman, Executive Director of the Fluoropolymer Manufacturers Group, to Mr. Charles Auer of the EPA, outlining their toxicology program, including a bio-monitoring test protocol and plans to discuss alternatives to fluoropolymer manufacturing processes.
|
2001 |
AR226-1009
|
XR2ypbpMpwpQ0J12D2wJeddRJ |
1 |
|
The document is a note summarizing a meeting held on March 28, 2001, between the EPA and 3M to discuss the status of 3M's testing program, phase-out plan for PFOS, and related OECD activities.
|
2001 |
AR226-1013
|
O1ZdN6odbBNoE9VBkdLvNjz61 |
1 |
|
3M submitted a TSCA 8(e) notice to the EPA detailing acute toxicity studies on perfluorooctane sulfonate (PFOS) conducted on honey bees, reporting a contact LD50 of 59.7 mg/Kg (moderately toxic) and an oral LD50 of 5 mg/Kg (highly toxic).
|
2001 |
AR226-1016
|
MJmManMjvpLzKeozZ7XwpGxra |
1 |
|
The document is a letter from the EPA to DuPont Haskell Laboratory requesting clarification on why results related to ammonium perfluorooctanoate (PFOA) were submitted as voluntary rather than under TSCA Section 8(e), given potential human health hazard concerns.
|
2001 |
AR226-1025
|
g2daZ926nLq4mqkyLORLbrVZ9 |
1 |
|
The document is a letter from the EPA to 3M Company regarding the submission of information on perfluorooctane sulfonates (PFOS) and related compounds, confirming its placement in the TSCA Public Docket as part of Administrative Record 226.
|
2001 |
AR226-1031
|
jN3L70pjzML3ez0m0Ln4qKnoO |
1 |
|
3M submitted two studies on perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) related to clinical chemistry and health outcomes from employee participants in their Fluorochemical Medical Surveillance Program to the EPA as part of their ongoing dialogue regarding fluorochemicals.
|
2001 |
AR226-1046
|
q51bGRm7bjaKOkQQ3RNaVXkK |
1 |
|
This letter from DuPont's corporate counsel, Andrea V. Malinowski, informs the EPA that certain documents related to a lawsuit against DuPont are claimed as TSCA Confidential Business Information, while others may be made public.
|
2001 |
AR226-1245
|
mp3rDVaggVqkzgRbDJG2j67ad |
1 |
|
This document lists various studies and reports related to fluorinated surfactants and repellents, including analyses of PFOS and PFOA levels in different contexts, with submission dates to the EPA noted for each entry.
|
2001 |
AR226-1294
|
0Jamgvbj6rMnj26RR2Bxqp6yM |
1 |
|
The document is a letter from the EPA to DuPont Haskell Laboratory requesting clarification on why results related to ammonium perfluorooctanoate (PFOA) were submitted as voluntary rather than under TSCA Section 8(e), given the potential human health hazard concerns indicated by human blood serum tests.
|
2001 |
AR226-1557
|
vB36dMw4V0ZqMBrnO340apVqm |
1 |
|
The document is a letter from the EPA requesting DuPont Haskell Laboratory to provide the complete data set of blood concentrations related to Ammonium Perfluorooctanoate (AFPO) as summarized in their report, following a previous inquiry.
|
2001 |
AR226-1559
|
pXoLYjyrknaBEV7YgwBJ2zD6 |
1 |
|
The document discusses concerns raised by an engineer regarding the poor recovery rate (25%) of the analytical technique used for measuring surfactants, including PFOA, at Parkersburg, which may lead to previously reported results being significantly underestimated and potentially exceeding the safe drinking water level of 1 ppb.
|
2001 |
AR226-1677
|
B8Z0e9B6Z87wL8d1vxn22kQ6m |
1 |
|
DuPont expresses concerns about potential increases in PFOA levels above the company's conservative exposure guideline of 1 ppb due to new analytical techniques, and plans to discuss these concerns with EPA Region 3 to avoid mandatory provision of alternative drinking water.
|
2001 |
AR226-1680
|
5LBn0ZwnDY7Rz0qwG6KbqLnb4 |
1 |
|
The document discusses a request from DuPont representatives to meet with EPA Region 3 to express concerns about the use of their CEG as a screening level for health risks related to PFOA, while also planning to present a new analytical method and sampling protocol.
|
2001 |
AR226-1681
|
3N673kVDNOn3xLVMYjnVOD8b3 |
1 |
|
Unreadable document.
|
2001 |
AR226-1683
|
3NEVJLgo8RXvoOzELKr7kNj8y |
1 |
|
The document discusses a communication regarding the assessment of chronic versus acute exposures to PFOA, highlighting a disagreement with the West Virginia Department of Environmental Protection regarding focus on annual average concentrations in the community versus short-term exposure limits.
|
2001 |
AR226-1684
|
DvxRpB5RXZq7zdyYxqnVYeQjd |
1 |
|
The document discusses an upcoming meeting regarding new drinking water concentration testing for PFOA, indicating expectations of significantly higher readings than previously reported, and the need to manage communication with regulators to avoid panic over potential contamination.
|
2001 |
AR226-1685
|
re4dDQOvvXYv9BOKk4zRB7wVv |
1 |
|
The document discusses a meeting with EPA Region 3 regarding PFOA, highlighting the need for updated primate study results, air monitoring data from DuPont, and the implications of new analytical protocols on PFOA serum and water concentration measurements.
|
2001 |
AR226-1686
|
x5Dy55q24pL1kRx4wjRp5YrR6 |
1 |
|
The document discusses a communication from Jack S. Mandel regarding his potential collaboration with DuPont on PFOA-related issues, indicating that 3M has no objection to his involvement as long as confidentiality is maintained between the two companies.
|
2001 |
AR226-1688
|
RJKbNjejkJ9nV8x2EDR2rZnB |
1 |
|
The document announces that following negotiations, 3M will voluntarily phase out perfluorooctanyl sulfonate (PFOS) chemistry used in various products, with the EPA indicating it will monitor the phase-out and assess potential regulatory actions if necessary.
|
2000 |
AR226-0000
|
ykz222jZ3dvYZDMwzRDD9wYMr |
1 |
|
This document is a correspondence from Larry R. Zobel of 3M to Dr. Oscar Hernandez at the US EPA, providing previously omitted documents related to studies on PFOS and PFOA, including a fertility and developmental toxicity study in rats.
|
2000 |
AR226-0001
|
mpOaeGv28OXkV5BY9NGa2RO5b |
1 |
|
This correspondence from 3M's Medical Director, Larry R. Zobel, clarifies findings from a two-generation reproduction study on potassium perfluorooctanesulfonate (PFOS), stating that there were no significant effects on pup survival or growth at the 0.4 mg/kg/day dose, contrary to earlier reports.
|
2000 |
AR226-0002
|
oe5g96njYYw5307mKrVBp3ZnX |
6 |
|
3M is voluntarily providing the EPA with additional information on perfluorooctanesulfonate (PFOS), including studies on pharmacokinetics, teratology, and epidemiology, as part of ongoing discussions regarding fluorochemistry.
|
2000 |
AR226-0003
|
nmZ079Gg25xEaoo7R305xEEO1 |
10 |
|
This document details a series of studies conducted by 3M on the dermal absorption and pharmacokinetics of perfluorooctanesulfonate (PFOS) in New Zealand white rabbits to assess the absorption capacity of low-molecular-weight manufacturing residuals.
|
2000 |
AR226-0009
|
gbnqByLxk1bJ3E4n8gZMZ56BL |
4 |
|
The document summarizes an oral developmental toxicity study of potassium perfluorooctanesulfonate (PFOS) in rats, conducted by Riker Laboratories, which found maternal toxicity at the highest dose but no significant fetal toxicity, although a developmental eye abnormality was noted across all dose groups, leading to the conclusion that PFOS was teratogenic.
|
2000 |
AR226-0013
|
v19m6DyZ1YLy06agOOQLo0N4q |
3 |
|
This final report from 3M Environmental Laboratory concludes that there was no detectable dermal absorption of FC-95 (the potassium salt of perfluorooctanesulfonic acid, or PFOS) in rabbits at low dose levels, indicating that these doses may be insufficient to assess dermal absorption.
|
2000 |
AR226-0011
|
QXqEZqrr9N5QL9DLEdn7b73b6 |
95 |
|
The document is a final report from 3M Environmental Laboratory detailing an analytical study on the pharmacokinetics of the fluorinated compound FC-95 (T-6049) in rabbits, which confirmed the presence of perfluorooctanesulfonate in liver and serum after intravenous dosing.
|
2000 |
AR226-0012
|
jB9rw4oRY4J64D9pO9KK8Qddk |
82 |
|
The document outlines various analytical methods developed by 3M Environmental Laboratory for the extraction and analysis of Potassium Perfluorooctanesulfonate (PFOS) and other fluorochemicals from serum, liver, and urine using HPLC-Electrospray/Mass Spectrometry, detailing method numbers and adoption dates.
|
2000 |
AR226-0024
|
a4BNvgkVn1VwpZ9EQoVG222BR |
15 |
|
This document is a correspondence from 3M confirming the submission of a non-confidential version of a toxicological study on perfluorooctane sulfonates to the EPA, following a request from EPA's Terry O'Brien.
|
2000 |
AR226-0037
|
Rjda4dkJ0EnNOXd4x2amgYXvz |
1 |
|
This is a letter from the EPA's Office of Prevention, Pesticides and Toxic Substances, dated May 25, 2000, regarding information on perfluorooctane sulfonates, including a reference to additional studies and data submitted by 3M.
|
2000 |
AR226-0040
|
Lp1pYjZyn4enJgjnx41ggoX9z |
5 |
|
3M is requesting a one-week extension to respond to the EPA's information request regarding perfluorooctane sulfonic acid (PFOS) due to operational disruptions and seeks to discuss interpretation questions related to previous communications with the EPA.
|
2000 |
AR226-0041
|
KRJvJEY2mV738X4294npky0M0 |
1 |
|
The document outlines various reports and studies conducted by 3M regarding the health effects of Perfluorooctanesulfonate (PFOS) on male employees at their fluorochemical production facilities, including epidemiological investigations and assessments of serum fluorochemical levels.
|
2000 |
AR226-0030
|
jwend2rXG0aYvx7yVkDee775 |
190 |
|
3M submitted a "Use and Exposure Information Profile" to the EPA detailing the use and exposure related to perfluorooctane sulfonic acid (PFOS) and its salt forms, emphasizing that the majority of their fluorochemical production involves higher molecular weight derivatives and that less than 200,000 lbs/year of PFOS and its salts are commercialized as finished products.
|
2000 |
AR226-0042
|
10vK5QrL2dLnN3z9OV2v9G0Ya |
2 |
|
The document provides a voluntary use and exposure information profile for perfluorooctane sulfonate (PFOS) and its various salt forms produced by 3M Company, detailing their manufacturing process, site locations, and estimated distribution quantities.
|
2000 |
AR226-0043
|
penGV3Rw4jbrOL3zJwwRvDrQj |
30 |
|
3M is providing the EPA with additional voluntary information on perfluorooctane sulfonates, including studies on their environmental properties and health effects, as part of ongoing discussions regarding fluorochemistry.
|
2000 |
AR226-0044
|
LJDJQxZJYrJx2wQxeE5OXyoZz |
31 |
|
The document contains various laboratory reports and summaries related to the physical and chemical properties of perfluorooctanesulfonate (PFOS), including studies on its melting point, vapor pressure, partition coefficient, and solubility, conducted by Wildlife International, Ltd. and 3M Environmental Lab.
|
2000 |
AR226-0055
|
LJNLOOMVd8dRpXzxzkraR0NvX |
39 |
|
The document outlines the design and structure of a Multi-City study submitted to 3M Environmental Laboratory, aimed at obtaining preliminary data on the dispersion of fluorochemical compounds, including PFOA, in the environment and their potential sources of human exposure.
|
2000 |
AR226-0063
|
DGQOz6M8jGX9EonnOQ7NBqd6o |
7 |
|
The document is a laboratory report from 3M Environmental Laboratory detailing screening studies on the aqueous photolytic degradation of Potassium Perfluorooctane Sulfonate (PFOS), which does not comply with US EPA Good Laboratory Practices Standards but has undergone quality assurance audits.
|
2000 |
AR226-1030
|
pOZrv4DLk4yQqank2rd5DeOB |
163 |
|
The document contains attachments to a letter discussing various studies and information related to the acute toxicity and genotoxicity of perfluorooctane sulfonate (PFOS) and its derivatives, conducted by Biosearch, Inc. and Hazelton Washington for 3M.
|
2000 |
AR226-0291
|
3N8rQ6jL91aJR9axGKG058EqE |
4 |
|
The document is a final report on a flow-through bioconcentration test of perfluorooctanesulfonate (PFOS) conducted with bluegill fish (Lepomis macrochirus) by Wildlife International, Ltd. for 3M Corporation, completed on June 21, 2001, in compliance with EPA Good Laboratory Practice Standards.
|
2000 |
AR226-1030
|
zo4nJKXKm9bRLea76BrbGg3b6 |
129 |
|
The document contains various studies and tests conducted by Riker Laboratories and other institutions on the acute toxicity, immunotoxicity, genotoxicity, and repeated-dose toxicity of N-ethylperfluorooctane sulfonamidoethyl acrylate (T-3493), a perfluorinated compound produced by 3M.
|
2000 |
AR226-0304
|
RJ8QJv6wBq94ZyLqN31Y200mX |
10 |
|
This final report details a 96-hour toxicity test of PFOS conducted with the freshwater alga Anabaena flos-aquae, sponsored by 3M Corporation and compliant with Good Laboratory Practice standards, with study completion on June 6, 2001.
|
2000 |
AR226-1030
|
x1nkDmBGBKwEnYo7gJ57Z8BEy |
57 |
|
The document is a final report on a 7-day toxicity test of PFOS (perfluorooctanesulfonic acid) conducted with duckweed (Lemna gibba G3) by Wildlife International, Ltd. for 3M Corporation, completed on March 26, 2001, and compliant with Good Laboratory Practice standards.
|
2000 |
AR226-1030
|
qa0Y1oxdYQ67YgRdv3mj05Xq5 |
47 |
|
This document is a final report on a 96-hour toxicity test of PFOS conducted by Wildlife International, Ltd. for 3M Corporation, which adhered to Good Laboratory Practice standards, with the study completed on March 26, 2001.
|
2000 |
AR226-1030
|
LpkGXoorJLwo8MJEvYv3zbjmw |
56 |
|
This final report details a 96-hour toxicity test of PFOS conducted on the marine diatom Skeletonema costatum by Wildlife International, Ltd. for 3M Corporation, indicating compliance with Good Laboratory Practice standards despite some exceptions in substance characterization and stability determination.
|
2000 |
AR226-1030
|
mmyJw4kYQXp8pZdgxvBmGV5nZ |
54 |
|
The document details various toxicity studies conducted by Riker Laboratories, Inc. on the perfluorinated compound N-ethyl perfluorooctane sulfonamido ethyl methacrylate (T-3494), including acute oral toxicity, skin irritation, ocular irritation, immunotoxicity, and genotoxicity assessments.
|
2000 |
AR226-0312
|
99nqqz0q4va3QK1LJR1MQNMJL |
10 |
|
This document contains studies and evaluations of the mutagenic activity of N-methylperfluorooctane sulfonamidoethyl acrylate (T-5869), conducted by NOTOX for 3M, including results from the Ames Salmonella test and chromosome aberration tests, all compliant with GLP standards.
|
2000 |
AR226-0317
|
x5OMKxbBN1kga1MpeOG2aEKyb |
24 |
|
The document contains attachments related to studies on the acute toxicity and pharmacokinetics of perfluorooctane sulfonate (PFOS) and its derivatives, specifically detailing various toxicity tests conducted by 3M and other laboratories.
|
2000 |
AR226-0320
|
rB0vdVgqn01GvMd0GypLRD7e0 |
32 |
|
The document is a final report on a frog embryo teratogenesis assay (FETAX) conducted by Wildlife International, Ltd. for 3M Corporation, assessing the effects of PFOS, with noted non-compliance to Good Laboratory Practice standards during the study.
|
2000 |
AR226-1030
|
NeGBEozavxRvkow9avN5v3Gww |
181 |
|
The document details a dietary acute study on the effects of perfluorooctanesulfonate (PFOS) conducted on mallard ducks, using a sample from 3M with a purity of 90.49%, to assess toxicity and establish LC50 values under controlled conditions.
|
2000 |
AR226-0102
|
LJB22x8Zw5bdR0Xwzz5Mkj2eQ |
8 |
|
This document contains various studies and reports related to the genotoxicity and mutagenicity of perfluorooctane sulfonate (PFOS), including evaluations conducted by different laboratories and institutions, primarily focusing on Ames tests and chromosomal aberration assays.
|
2000 |
AR226-0128
|
J3LKnQbyByJRJGer4rVVgMzQX |
12 |
|
The document evaluates mutagenicity studies on perfluorooctanesulfonate (PFOS), a degradation product of perfluorooctanesulfonylfluoride produced by 3M, to assess its potential mutagenic/genotoxic risks based on various toxicological studies conducted.
|
2000 |
AR226-0135
|
emXLYakkxVK3md08mq6JZr1ay |
12 |
|
The document contains attachments related to various toxicity studies of Perfluorooctane Sulfonate (PFOS) conducted by the International Research and Development Corporation and Covance Laboratories, detailing findings from subacute and chronic studies in monkeys and rats.
|
2000 |
AR226-0137
|
baEVvZ7rxgONJBNYLao4vEy43 |
41 |
|
The document details the findings from a microscopic review of liver sections from rats in a chronic PFOS study, indicating that centrolobular hepatocyte hypertrophy is present in certain male groups, with some changes deemed adaptive and others potentially adverse, leading to a determination of NOAEL and NOEL for liver histologic changes.
|
2000 |
AR226-0141
|
K6e5Vp4Mdo5KYYekaxRwYayxo |
11 |
|
This is a biodegradation study report prepared by Pace Analytical Services, Inc. for 3M, detailing the aerobic biodegradation of W-EtFOSE alcohol using microbial activity from municipal wastewater treatment sludge, with project dates from July 20, 2000, to October 1, 2000.
|
2000 |
AR226-1030
|
gDpw3xDBjX2Kzazoz7Z0818gJ |
56 |
|
3M submitted additional information to the EPA regarding perfluorooctane sulfonates and related compounds, including various CAS numbers, as part of ongoing discussions about fluorochemistry, while noting that some information is confidential business information.
|
2000 |
AR226-0333
|
BvMOL4jXQ1v8BOzxmrG5O1Mrm |
20 |
|
The document is a laboratory report from 3M detailing screening studies on the aqueous photolytic degradation of N-Ethylperfluorooctanesulfonamido-ethyl alcohol (N-EtFOSE Alcohol), indicating that the study was not conducted under Good Laboratory Practices but followed specific testing procedures.
|
2000 |
AR226-1030
|
zM6GjZpV0DvG7vm9MLK38zma |
166 |
|
The document announces that 3M will voluntarily phase out perfluorooctanyl sulfonate (PFOS) chemistry used in various products following negotiations with the EPA, with the agency committing to further evaluate potential risks to individuals and the environment.
|
2000 |
AR226-0000
|
jyNJq9dDR6pvKqbN4Zy9xOdrR |
1 |
|
This document is a correspondence from Larry R. Zobel of 3M to Dr. Oscar Hernandez at the US EPA, providing additional documents related to studies on PFOS and PFOA that were inadvertently omitted from a previous package.
|
2000 |
AR226-0001
|
a4j4DeMN79KxBExEeL0n8QYNR |
1 |
|
The document is a cover letter from Bill Weppner of 3M to Charles Auer at the EPA, submitting various reports related to PFOS, including interim findings on serum half-lives, acute toxicity studies, and genotoxicity assessments.
|
2000 |
AR226-0979
|
DG0DeajeMOVqGYr09NB8eLbdB |
6 |
|
The document describes an experiment using thermospray mass spectrometry to assess the volatility of FC-95 and FC-143, specifically investigating their vapor pressure at room temperature and their removal from solutions when air is bubbled through them.
|
2000 |
AR226-1030
|
8O2JZdnyvGaoz9aRwgj7zNQB5 |
20 |
|
The interim report from 3M Company details a study on the serum half-lives of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) in retired fluorochemical production employees, indicating that PFOS has a half-life significantly lower than previous estimates and that PFOA's half-life is approximately one year.
|
2000 |
AR226-0979
|
Rp39kjj7EVa6bRxxRdD79n1DB |
9 |
|
3M is providing the EPA with additional information on perfluorooctane sulfonates and related compounds, including studies on health effects and environmental science, as part of ongoing discussions regarding fluorochemistry.
|
2000 |
AR226-0979
|
15L6vkZ7oJ9vnw0XDVMJxxXgj |
13 |
|
This memo details the results of pooled human serum samples for PFOS collected from European blood banks in 1999, indicating consistent findings with previous data, with average concentrations of PFOS in Belgium, the Netherlands, and Germany being 17 ppb, 53 ppb, and 37 ppb, respectively.
|
2000 |
AR226-0979
|
qnyLjVkB5yXjVdwJxLgR8BvM |
1 |
|
The document is a draft electron microscopy report detailing the evaluation of liver tissues from cynomolgus monkeys in a 26-week toxicity study of perfluorooctane sulfonic acid (PFOS), indicating that lesions observed during treatment have resolved in recovery animals.
|
2000 |
AR226-0979
|
nkQVenbwyeLyRdO5av37EqGvz |
34 |